SÍNDROME OVARIANA METABÓLICA POLIENDÓCRINA E SAÚDE INTEGRAL DA MULHER: INTERFACES ENTRE DISFUNÇÃO HORMONAL, METABOLISMO E FERTILIDADE
DOI:
https://doi.org/10.63330/aurumpub.070-007Palavras-chave:
Disfunção mitocondrial, Hiperandrogenismo, Microbiota intestinal, Qualidade de vida, Resistência à insulinaResumo
A Síndrome Ovariana Metabólica Poliendócrina (SOMP) apresenta manifestações que ultrapassam o sistema reprodutivo, envolvendo alterações metabólicas, inflamatórias, intestinais e celulares. Este estudo teve como objetivo analisar as principais interfaces fisiopatológicas da condição e suas repercussões sobre a função ovariana e a qualidade de vida da mulher. Trata-se de uma revisão integrativa da literatura, de abordagem qualitativa e caráter exploratório, realizada nas bases PubMed/MEDLINE, Scopus, Web of Science e Embase, considerando publicações entre 2021 e 2026. Após as etapas de identificação, triagem e elegibilidade, foram incluídos 17 estudos. Os estudos evidenciaram relações entre resistência à insulina, hiperandrogenismo, disbiose intestinal, inflamação e alterações na função ovariana. Também foram identificadas alterações mitocondriais, deficiência de NAD⁺ e comprometimento da comunicação entre oócito e células da granulosa, associadas a prejuízos no desenvolvimento folicular e na competência oocitária. Estudos experimentais e clínicos apontaram ainda possíveis efeitos de intervenções nutricionais, compostos bioativos e estratégias direcionadas à microbiota. Portanto, é necessário a compreensão integrada dos mecanismos envolvidos pode favorecer abordagens mais individualizadas de prevenção e cuidado, considerando as dimensões metabólica, reprodutiva e psicossocial.
Downloads
Referências
BARDIN, L. Análise de conteúdo. São Paulo: Edições 70, 2011.
CAO, M. et al. Adipose mesenchymal stem cell-derived exosomal microRNAs ameliorate polycystic ovary syndrome by protecting against metabolic disturbances. Biomaterials, v. 288, p. 121739, 2022. DOI: https://doi.org/10.1016/j.biomaterials.2022.121739. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0142961222003799?via%3Dihub. Acesso em: 4 ago. 2026.
CHEN, M. et al. Resveratrol ameliorates polycystic ovary syndrome via transzonal projections within oocyte-granulosa cell communication. Theranostics, v. 12, n. 2, p. 782–795, 2022. DOI: https://doi.org/10.7150/thno.67167. Disponível em: https://www.thno.org/v12p0782.htm. Acesso em: 4 ago. 2026.
CINCIONE, R. I. et al. Effects of mixed of a ketogenic diet in overweight and obese women with polycystic ovary syndrome. International Journal of Environmental Research and Public Health, v. 18, n. 23, p. 12490, 2021. DOI: https://doi.org/10.3390/ijerph182312490. Disponível em: https://www.mdpi.com/1660-4601/18/23/12490. Acesso em: 4 ago. 2026.
FARHADI-AZAR, M. et al. The prevalence of polycystic ovary syndrome, its phenotypes and cardio-metabolic features in a community sample of Iranian population: Tehran Lipid and Glucose Study. Frontiers in Endocrinology, v. 13, 2022. DOI: https://doi.org/10.3389/fendo.2022.825528. Disponível em: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.825528/full. Acesso em: 4 ago. 2026.
GIL, A. C. Métodos e técnicas de pesquisa social. 6. ed. São Paulo: Atlas, 2008.
HAN, Q. et al. Androgen-induced gut dysbiosis disrupts glucolipid metabolism and endocrinal functions in polycystic ovary syndrome. Microbiome, v. 9, p. 101, 2021. DOI: https://doi.org/10.1186/s40168-021-01046-5. Disponível em: https://link.springer.com/article/10.1186/s40168-021-01046-5. Acesso em: 4 ago. 2026.
LI, C. et al. Eight-hour time-restricted feeding improves endocrine and metabolic profiles in women with anovulatory polycystic ovary syndrome. Journal of Translational Medicine, v. 19, p. 148, 2021a. DOI: https://doi.org/10.1186/s12967-021-02817-2. Disponível em: https://link.springer.com/article/10.1186/s12967-021-02817-2. Acesso em: 4 ago. 2026.
LI, T. et al. Tempol ameliorates polycystic ovary syndrome through attenuating intestinal oxidative stress and modulating of gut microbiota composition-serum metabolites interaction. Redox Biology, v. 41, p. 101886, 2021b. DOI: https://doi.org/10.1016/j.redox.2021.101886. Disponível em: https://www.sciencedirect.com/science/article/pii/S2213231721000343?via%3Dihub. Acesso em: 4 ago. 2026.
LIANG, Z.; DI, N.; LI, L.; YANG, D. Gut microbiota alterations reveal potential gut–brain axis changes in polycystic ovary syndrome. Journal of Endocrinological Investigation, v. 44, p. 1727–1737, 2021. DOI: https://doi.org/10.1007/s40618-020-01481-5. Disponível em: https://link.springer.com/article/10.1007/s40618-020-01481-5. Acesso em: 4 ago. 2026.
LIAO, B. et al. Effects of androgen excess-related metabolic disturbances on granulosa cell function and follicular development. Frontiers in Endocrinology, v. 13, 2022. DOI: https://doi.org/10.3389/fendo.2022.815968. Disponível em: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.815968/full. Acesso em: 4 ago. 2026.
PRATAMA, G. et al. Mechanism of elevated LH/FSH ratio in lean PCOS revisited: a path analysis. Scientific Reports, v. 14, p. 8229, 2024. DOI: https://doi.org/10.1038/s41598-024-58064-0. Disponível em: https://www.nature.com/articles/s41598-024-58064-0. Acesso em: 4 ago. 2026.
QIAN, Y. et al. Integrated lipid metabolomics and proteomics analysis reveal the pathogenesis of polycystic ovary syndrome. Journal of Translational Medicine, v. 22, p. 364, 2024. DOI: https://doi.org/10.1186/s12967-024-05167-x. Disponível em: https://link.springer.com/article/10.1186/s12967-024-05167-x. Acesso em: 4 ago. 2026.
TABASSUM, F. et al. Impact of polycystic ovary syndrome on quality of life of women in correlation to age, basal metabolic index, education and marriage. PLOS ONE, v. 16, n. 3, p. e0247486, 2021. DOI: https://doi.org/10.1371/journal.pone.0247486. Disponível em: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247486. Acesso em: 4 ago. 2026.
WANG, Y. et al. NAD+ deficiency and mitochondrial dysfunction in granulosa cells of women with polycystic ovary syndrome. Biology of Reproduction, v. 105, n. 2, p. 371–380, 2021. DOI: https://doi.org/10.1093/biolre/ioab078. Disponível em: https://academic.oup.com/biolreprod/article-abstract/105/2/371/6288483?redirectedFrom=fulltext. Acesso em: 4 ago. 2026.
YU, O. et al. Incidence, prevalence, and trends in polycystic ovary syndrome diagnosis: a United States population-based study from 2006 to 2019. American Journal of Obstetrics and Gynecology, v. 229, n. 1, p. 39.e1–39.e12, 2023. DOI: https://doi.org/10.1016/j.ajog.2023.04.010. Disponível em: https://www.ajog.org/article/S0002-9378(23)00241-7/abstract. Acesso em: 4 ago. 2026.
YUN, C. et al. The microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice. Nature Metabolism, v. 6, p. 947–962, 2024. DOI: https://doi.org/10.1038/s42255-024-01041-8. Disponível em: https://www.nature.com/articles/s42255-024-01041-8. Acesso em: 4 ago. 2026.
ZHANG, H. et al. Relationship between body composition, insulin resistance, and hormonal profiles in women with polycystic ovary syndrome. Frontiers in Endocrinology, v. 13, 2023. DOI: https://doi.org/10.3389/fendo.2022.1085656. Disponível em: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.1085656/full. Acesso em: 4 ago. 2026.
ZHAO, R. et al. Multiomics analysis reveals molecular abnormalities in granulosa cells of women with polycystic ovary syndrome. Frontiers in Genetics, v. 12, 2021. DOI: https://doi.org/10.3389/fgene.2021.648701. Disponível em: https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.648701/full. Acesso em: 4 ago. 2026.
Downloads
Publicado
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
